3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
4
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
33
Dermatologic
4
Sarcoma
3
Gynecologic
3
Tumor-Agnostic
2
Other solid neoplasm
2
Gastrointestinal
2
Thoracic
1
Other hematologic neoplasm
1
NET
1
Lymphoid
1
Endocrine
1
CNS
1
Conditions
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma
1
Lymphoma
1
Leukemia
1
Hematologic Neoplasms
1
Breast Neoplasms
1
Interventions
Rituximab
689
Cyclophosphamide
614
Vincristine
285
Etoposide
272
Doxorubicin
271
Cytarabine
230
Prednisone
228
Methotrexate
221
fludarabine phosphate
189
Filgrastim
187
Dexamethasone
180
fludarabine
175
Lenalidomide
165
Radiotherapy
128
Melphalan
127
Peripheral Blood Stem Cell Transplantation
123
Busulfan
118
Bendamustine Hydrochloride
116
Granulocyte Colony-Stimulating Factor
113
Bortezomib
112
ibrutinib
111
Mycophenolic Acid
110
venetoclax
106
Whole-Body Irradiation
106
Tacrolimus
105
obinutuzumab
104
Gemcitabine
92
zanubrutinib
81
Specimen Handling
80
Cyclosporine
76
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
ribociclib
×
Lymphoid
×
Clear all
NCT02187783
2019-07-18
SIGNATURE
Novartis
Phase 2
Completed
106 enrolled
16 charts